|
Liver carcinoma
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Although we did not find any significant results in total analysis (all p>0.05), our stratified data showed that SNP rs9912300 in ACLY gene was significantly associated with overall survival of HCC patients with lower AFP level and SNP rs11871275 in ACACA gene was significantly associated with overall survival of HCC patients with higher AFP level.
|
25735330 |
2015 |
|
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
|
21147110 |
2011 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
|
Congestive heart failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
|
Left-Sided Heart Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
|
Heart Failure, Right-Sided
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
|
Myocardial Failure
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
|
Heart Decompensation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice.
|
26670611 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Orchestrated downregulation of genes involved in oxidative metabolic pathways in obese vs. lean high-fat young male consumers.
|
20882379 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ACLY plays a pivotal role in cancer metabolism through the potential deprivation of cytosolic citrate, a process promoting glycolysis through the enhancement of the activities of PFK 1 and 2 with concomitant activation of oncogenic drivers such as PI3K/AKT which activate ACLY and the Warburg effect in a feed-back loop.
|
31830561 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ACL model in the second-line targeted therapy setting may predict outcomes more accurately than the Memorial Sloan Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium models.
|
31400935 |
2020 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patient-reported outcomes 1 to 5 years after ACL reconstruction: effect of combined injury, and associations with MRI-defined osteoarthritis features.
|
30762314 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
ACLY plays a pivotal role in cancer metabolism through the potential deprivation of cytosolic citrate, a process promoting glycolysis through the enhancement of the activities of PFK 1 and 2 with concomitant activation of oncogenic drivers such as PI3K/AKT which activate ACLY and the Warburg effect in a feed-back loop.
|
31830561 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The ACL model in the second-line targeted therapy setting may predict outcomes more accurately than the Memorial Sloan Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium models.
|
31400935 |
2020 |
|
Degenerative polyarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The orientation of the femoral tunnel did not predict the long-term subjective outcome, functional outcome or the development of osteoarthritis in patients undergoing non-anatomic ACL reconstruction.
|
30707249 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radiographic signs of progression of osteoarthritis were reported in six studies, where severe signs of degeneration (grade 3 or 4 according Kellgren-Lawrence or Ahlbäck classification) shifted from 4 out of 216 knees (1.9%) before surgery to 28 out of 187 knees (15%) following ACL reconstruction, after a mean period of follow-up ranging from 32 to 64 months.
|
30944945 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
OARSI (Osteoarthritis Research Society International) score of ACL-T/Ex group showed highest among 4 groups (<i>P</i> < 0.001).
|
31718284 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACL and meniscal injuries increase the risk of primary total knee replacement for osteoarthritis: a matched case-control study using the Clinical Practice Research Datalink (CPRD).
|
29331994 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
At a median of 22 years of follow-up, this study shows that patellar tendon autograft ACL reconstruction provides good clinical outcomes, with clinically objective knee stability and a 28% prevalence of OA.
|
31103415 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACL transection (ACL-x) was employed to determine if CCL2<sup>-/-</sup> CCR2<sup>-/-</sup> mice were protected against osteoarthritis (OA) (n = 6/group).
|
31424112 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients who were treated with grafts other than autogenous quadruple hamstring tendon, and had concomitant ligamentous injury, revisional ACL reconstruction, previous operative history of the affected knee, osseous deformity and osteoarthritis were excluded.
|
31169629 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increasing evidences highlight the central role of ACLY, conferring a great therapeutic potential to this enzyme as a key target for the treatment of cancer.
|
30195238 |
2018 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, several genes involved in the "Central carbon metabolism pathway in cancer", as reported in the Kyoto Encyclopedia of Genes and Genomes, were either up- (ACLY, ERBB2, GCK, MYC, PGM, PKFB2, SLC1A5, SLC7A5, SLC16A3,) or down- (IDH, MDH1, OGDH, P53, PDK) regulated in response to the drug association.
|
29970880 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed ACLY in normal and OA human knee chondrocytes and cartilages by Western blotting and immunohistochemistry, and quantified acetyl-CoA fluorometrically.
|
29929979 |
2018 |